DGHS advisory drops all medicines from revised Covid management guidelines
It added stressed on healthy balanced diet with proper hydration, and asked patients and their families to stay connected and engage in positive talks through phone, video-calls, etc.
The Union health ministry’s directorate general of health services (DGHS) has overhauled Covid-19 treatment guidelines and removed all medicines, except antipyretic (fever) and antitussive (cold), for asymptomatic and mild cases.

The revised guidelines, issued on May 27, effectively dropped all drugs that doctors have been prescribing even to asymptomatic or mildly symptomatic Covid-19 patients such as hydroxychloroquine, ivermectin, doxycycline, zinc, multivitamins etc. The guidelines also dissuade medical practitioners to prescribe unnecessary tests such as CT scan.
For asymptomatic cases, the guidelines said, no medication is required, while medications for other co-morbid conditions should be continued. “Patients are advised to seek tele consultation; and Covid-19 appropriate behaviour must be observed such as mask, strict hand hygiene and physical distancing,” the guidelines said.
It added stressed on healthy balanced diet with proper hydration, and asked patients and their families to stay connected and engage in positive talks through phone, video-calls, etc.
For tests, the advisory said, “Usually, no investigation is required at this stage.”
In mild cases, the guidelines recommended self-monitoring for fever, breathlessness, oxygen saturation (SpO2) or worsening of any symptoms. People may take anti-pyretic and anti-tussive for symptomatic relief, and inhalational of budesonide (given via metered dose inhaler with space device) at a dose of 800 mcg twice a day for 5 days for cough, the guidelines said. “No other Covid-19 specific medication required. Patient may have to be investigated further if symptoms persist or deteriorate,” it recommended.
ABOUT THE AUTHORRhythma KaulRhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More

E-Paper


